Patent application number | Description | Published |
20080318978 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ALDOSTERONE SYNTHASE INHIBITORS - The application relates to novel heterocyclic compounds of the general formula (I) in which R, R | 12-25-2008 |
20090111840 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors - The patent application relates to new heterocyclic compounds of the general formula (I) in which R, R | 04-30-2009 |
20090325947 | NITRATE ESTERS OF PIPERIDINES - The application relates to novel nitrate ester derivatives of substituted piperidines of the general formula (I), wherein R | 12-31-2009 |
20100010015 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors - The patent application relates to new heterocyclic compounds of the general formula (I) in which A, R, R | 01-14-2010 |
20100029694 | Heterocyclic compounds and their use as aldosterone synthase inhibitors - Heterocyclic compounds of the general formula (I) | 02-04-2010 |
20100168145 | FUSED IMIDAZOLE DERIVATIVES AND USE THEREOF AS ALDOSTERONE SYNTHASE INHIBITORS - The patent application relates to new heterocyclic compounds of the general formula (I) in which A, R, R | 07-01-2010 |
20100173919 | PHARMACEUTICAL COMPOSITION USING ALISKIREN AND AVOSENTAN - The present invention relates to a pharmaceutical composition and method of achieving a therapeutic effect including, but not limited to, the treatment of hypertension, kidney or heart disease in an animal, preferably a mammal including a human subject, using (i) SPP100/aliskiren or a pharmaceutically acceptable salt thereof in combination with (ii) SPP301/avosentan or a pharmaceutically acceptable salt thereof and (iii) a pharmaceutically acceptable carrier. | 07-08-2010 |
20120295888 | USE OF AN ADRENAL HORMONE-MODIFYING AGENT - The present invention relates to a method of treating a disease or disorder characterised by increased stress hormone levels and/or decreased androgen hormone levels in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): | 11-22-2012 |
20140171392 | Use of an Adrenal Hormone-Modifying Agent - The present invention relates to a method of treating a disease or disorder characterised by increased stress hormone levels and/or decreased androgen hormone levels in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): | 06-19-2014 |
Patent application number | Description | Published |
20150058586 | Guarded Memory Access in a Multi-Thread Safe System Level Modeling Simulation - Methods, systems, and machine readable medium for multi-thread safe system level modeling simulation (SLMS) of a target system on a host system. An example of a SLMS is a SYSTEMC simulation. During the SLMS, SLMS processes are executed in parallel via a plurality of threads. SLMS processes represent functional behaviors of components within the target system, such as functional behaviors of processor cores. Deferred execution may be used to defer execution of operations of SLMS processes that access a shared resource. Multi-thread safe direct memory interface (DMI) access may be used by a SLMS process to access a region of the memory in a multi-thread safe manner. Access to regions of the memory may also be guarded if they are at risk of being in a transient state when being accessed by more than one SLMS process. | 02-26-2015 |
20150058854 | Direct Memory Interface Access in a Multi-Thread Safe System Level Modeling Simulation - Methods, systems, and machine readable medium for multi-thread safe system level modeling simulation (SLMS) of a target system on a host system. An example of a SLMS is a SYSTEMC simulation. During the SLMS, SLMS processes are executed in parallel via a plurality of threads. SLMS processes represent functional behaviors of components within the target system, such as functional behaviors of processor cores. Deferred execution may be used to defer execution of operations of SLMS processes that access a shared resource. Multi-thread safe direct memory interface (DMI) access may be used by a SLMS process to access a region of the memory in a multi-thread safe manner. Access to regions of the memory may also be guarded if they are at risk of being in a transient state when being accessed by more than one SLMS process. | 02-26-2015 |
20150058859 | Deferred Execution in a Multi-thread Safe System Level Modeling Simulation - Methods, systems, and machine readable medium for multi-thread safe system level modeling simulation (SLMS) of a target system on a host system. An example of a SLMS is a SYSTEMC simulation. During the SLMS, SLMS processes are executed in parallel via a plurality of threads. SLMS processes represent functional behaviors of components within the target system, such as functional behaviors of processor cores. Deferred execution may be used to defer execution of operations of SLMS processes that access a shared resource. Multi-thread safe direct memory interface (DMI) access may be used by a SLMS process to access a region of the memory in a multi-thread safe manner. Access to regions of the memory may also be guarded if they are at risk of being in a transient state when being accessed by more than one SLMS process. | 02-26-2015 |